← Back to patent-cliff list
CAS 123-38-6
Methyl acetaldehydepropionaldehydePropanal
Codes: (II)101438-35-a, ROTI-013, Cefcamate Pivoxil Hydrochloride-029
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateRestless legs syndromeRotigotineParkinson's diseaseRotigotineSubstance-related disorderRotigotineDrug-related adverse effects and reactionsRotigotineTissue adhesionsRotigotinePostoperative painRotigotinePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelBacterial infectionCefcamate Pivoxil Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Rotigotine | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Cefcamate Pivoxil Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-(2-Propynyloxy)tetrahydropyran→Methyl acetaldehyde→6-(oxan-2-yloxy)hex-4-yn-3-ol→(4Z)-6-(oxan-2-yloxy)hex-4-en-3-ol→5-(hydroxymethyl)-2,4,4-trimethyl-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→(4Z)-6-(oxan-2-yloxy)hex-4-en-3-one→lithium(1+) ion 1-ethoxy-2-methylprop-1-en-1-olate→ethyl 2,2-dimethyl-3-[(oxan-2-yloxy)methyl]-5-oxoheptanoate→2,4,4-trimethyl-5-[(oxan-2-yloxy)methyl]-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→5-formyl-2,4,4-trimethyl-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→(5E)-2,4,4-trimethyl-3-oxo-5-{[(triisopropylsilyl)oxy]methylidene}cyclohex-1-en-1-yl 2,2-dimethylpropanoate→(5S)-5-formyl-5-hydroxy-2,4,4-trimethyl-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→(1S)-1-hydroxy-4,6,6-trimethyl-5-oxo-3-[(triisopropylsilyl)oxy]cyclohex-3-ene-1-carbaldehyde→(1S,5Z)-1-hydroxy-4,6,6-trimethyl-5-[(phenylsulfanyl)methylidene]-3-{[tris(propan-2-yl)silyl]oxy}cyclohex-3-ene-1-carbaldehyde→(1S,5S,12R,13R)-12-(benzyloxy)-3,3-di-tert-butyl-15,18,18-trimethyl-13-(phenylsulfanyl)-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-trien-16-one→{[(benzyloxy)(6-bromocyclohexa-1,5-dien-1-yl)methoxy]methyl}benzene→(1S,5E)-1-[(S)-{6-[bis(benzyloxy)methyl]cyclohexa-1,5-dien-1-yl}(hydroxy)methyl]-4,6,6-trimethyl-5-[(phenylsulfanyl)methylidene]-3-[(triisopropylsilyl)oxy]cyclohex-3-en-1-ol→{[(4S,5S,9E)-4-{6-[bis(benzyloxy)methyl]cyclohexa-1,5-dien-1-yl}-2,8,10,10-tetramethyl-9-[(phenylsulfanyl)methylidene]-1,3-dioxa-2-boraspiro[4.5]dec-7-en-7-yl]oxy}tris(propan-2-yl))silane→(1S,5S,12R,13R)-12-(benzyloxy)-3,15,18,18-tetramethyl-13-(phenylsulfanyl)-2,4-dioxa-3-boratetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-trien-16-one→(1S,5S,12R,13R,16S)-12-(benzyloxy)-3,3-di-tert-butyl-16-[(tert-butyldimethylsilyl)oxy]-15,18,18-trimethyl-13-(phenylsulfanyl)-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-triene→(1S,5S,7R,10S,12S,16S)-12-(benzyloxy)-3,3-di-tert-butyl-16-[(tert-butyldimethylsilyl)oxy]-15,18,18-trimethyl-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6(11),14-diene-7,10-diol
2-(thiophen-2-yl)ethyl 4-methylbenzenesulfonate→5-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride→propionaldehyde→5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine→(S)-2-hydroxy-3-phenylpropanoic acid→(S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine (S)-2-hydroxy-3-phenylpropanoate→(S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride→(S)-6-(propylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
2-(2-Propynyloxy)tetrahydropyran→Methyl acetaldehyde→6-(oxan-2-yloxy)hex-4-yn-3-ol→(4Z)-6-(oxan-2-yloxy)hex-4-en-3-ol→5-(hydroxymethyl)-2,4,4-trimethyl-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→(4Z)-6-(oxan-2-yloxy)hex-4-en-3-one→lithium(1+) ion 1-ethoxy-2-methylprop-1-en-1-olate→ethyl 2,2-dimethyl-3-[(oxan-2-yloxy)methyl]-5-oxoheptanoate→2,4,4-trimethyl-5-[(oxan-2-yloxy)methyl]-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→5-formyl-2,4,4-trimethyl-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→(5E)-2,4,4-trimethyl-3-oxo-5-{[(triisopropylsilyl)oxy]methylidene}cyclohex-1-en-1-yl 2,2-dimethylpropanoate→(5S)-5-formyl-5-hydroxy-2,4,4-trimethyl-3-oxocyclohex-1-en-1-yl 2,2-dimethylpropanoate→(1S)-1-hydroxy-4,6,6-trimethyl-5-oxo-3-[(triisopropylsilyl)oxy]cyclohex-3-ene-1-carbaldehyde→(1S,5Z)-1-hydroxy-4,6,6-trimethyl-5-[(phenylsulfanyl)methylidene]-3-{[tris(propan-2-yl)silyl]oxy}cyclohex-3-ene-1-carbaldehyde→(1S,5S,12R,13R)-12-(benzyloxy)-3,3-di-tert-butyl-15,18,18-trimethyl-13-(phenylsulfanyl)-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-trien-16-one→{[(benzyloxy)(6-bromocyclohexa-1,5-dien-1-yl)methoxy]methyl}benzene→(1S,5E)-1-[(S)-{6-[bis(benzyloxy)methyl]cyclohexa-1,5-dien-1-yl}(hydroxy)methyl]-4,6,6-trimethyl-5-[(phenylsulfanyl)methylidene]-3-[(triisopropylsilyl)oxy]cyclohex-3-en-1-ol→{[(4S,5S,9E)-4-{6-[bis(benzyloxy)methyl]cyclohexa-1,5-dien-1-yl}-2,8,10,10-tetramethyl-9-[(phenylsulfanyl)methylidene]-1,3-dioxa-2-boraspiro[4.5]dec-7-en-7-yl]oxy}tris(propan-2-yl))silane→(1S,5S,12R,13R)-12-(benzyloxy)-3,15,18,18-tetramethyl-13-(phenylsulfanyl)-2,4-dioxa-3-boratetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-trien-16-one→(1S,5S,12R,13R,16S)-12-(benzyloxy)-3,3-di-tert-butyl-16-[(tert-butyldimethylsilyl)oxy]-15,18,18-trimethyl-13-(phenylsulfanyl)-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-triene→(1S,5S,7R,10S,12S,16S)-12-(benzyloxy)-3,3-di-tert-butyl-16-[(tert-butyldimethylsilyl)oxy]-15,18,18-trimethyl-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6(11),14-diene-7,10-diol
Cefcamate Pivoxil HydrochlorideOptimised routesteps: 1total yield: 184g(Cefcamate Pivoxil Hydrochloride-004)
Cefcamate Pivoxil HydrochlorideOptimised routesteps: 3total yield: 48.6g(Cefcamate Pivoxil Hydrochloride-004)
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 5-Methoxy-2-tetralone Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (S)-2-AMINO-5-METHOXYTETRALIN HYDROCHLORIDE Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | (S)-2-Amino-5-methoxytetralin Hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (S)-1,2,3,4-Tetrahydro-5-methoxy-N-propyl-2-naphthalenamine hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (S)-2-Amino-5-methoxytetralin (S)-mandelate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.